DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on June 21, 2006; DOI: 10.1124/dmd.106.010355


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.106.010355v1
34/9/1640    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liempd, S. M. v.
Right arrow Articles by Vermeulen, N. P.E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liempd, S. M. v.
Right arrow Articles by Vermeulen, N. P.E.


Received for publication April 7, 2006.
Revised June 7, 2006.
Accepted for publication June 16, 2006.

On-line Formation, Separation and Estrogen Receptor Affinity Screening of Cytochrome P450-derived Metabolites of Selective Estrogen Receptor Modulators

S. M. van Liempd 1, Jeroen Kool 1, W.M.A. Niessen 1, D.E. van Elswijk 2, H. Irth 2, Nico P.E. Vermeulen 1*

1 Vrije Universiteit Amsterdam 2 Kiadis B.V.

* Address correspondence to: E-mail: npe.vermeulen{at}few.vu.nl

Abstract

We have developed a fully automated bioreactor coupled to an on-line receptor affinity detection system. This analytical system provides detailed information on pharmacologically active metabolites of selective estrogen receptor modulators (SERMs) generated by cytochromes P450 (CYPs). We demonstrated this novel concept by investigating the metabolic activation of tamoxifen (TAM) and raloxifene (RAL) by CYP-containing pig and rat liver microsomes. The high resolution screening (HRS) system is based on the coupling of a CYP-bioreactor to an HPLC-based estrogen receptor alpha (ER{alpha}) affinity assay. CYP-derived metabolites of the SERMs were generated in the bioreactor, subsequently on-line trapped with solid phase extraction (SPE) and finally separated with gradient HPLC. Upon elution the metabolites were screened on affinity for ER{alpha} with an on-line HRS assay. With this HRS-system, we were able to follow time-dependently the formation of ER{alpha}-binding metabolites of tamoxifen and raloxifene. By analyzing the bio-affinity chromatograms with LC-MS/MS structural information of the pharmacologically active metabolites was obtained as well. For tamoxifen, 15 active and 6 non-active metabolites were observed of which 5 were of primary, 10 of secondary and 6 of as yet unknown order of metabolism. Raloxifene was biotransformed in 3 primary and 3 secondary metabolites. Tandem MS/MS analysis revealed that three of the observed active metabolites of raloxifene were not described before. This present automated HRS-system on-line coupled to a CYP-containing bioreactor and an ER{alpha}-affinity detector proved very efficient, sensitive and selective in metabolic profiling of SERMs.


Key words: analytical pharmacology/toxicology, bioactivation, cytochrome P450, drug discovery, drug disposition, high throughput screening, metabolite identification


This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C. J. Mark, R. Tatchum-Talom, D. S. Martin, and K. M. Eyster
Effects of estrogens and selective estrogen receptor modulators on vascular reactivity in the perfused mesenteric vascular bed
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2007; 293(5): R1969 - R1975.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.